P0599 Ustekinumab has the highest persistence in Crohn’s Disease, vedolizumab has the highest persistence in Ulcerative Colitis, and persistence declines from first- to fourth-line therapy
Abstract
Abstract Background Multiple advanced therapies (ATs) are available for Crohn’s disease (CD) and ulcerative colitis (UC), but optimal sequencing remains unclear. We evaluated 12-month persistence, an endpoint aligned with clinical trial outcomes, and characterised persistence patterns across drug classes and lines of therapy. Methods We interrogated the Persistence Australian National IBD Cohort (PANIC5) registry from 2017-2021, covering all Australian prescribing data for CD and UC. Persistence at 12 months was defined as the proportion of patients remaining on AT. Patients with
Fields of Study & Subjects
Inflammatory Bowel Disease
Biosimilars and Bioanalytical Methods
Autoimmune and Inflammatory Disorders
Publication details
- Journal / source
- Journal of Crohn s and Colitis
- Publisher
- Oxford University Press (OUP)
- Volume
- 20
- Issue
- Supplement_1
- Publication date
- 1 January 2026
- Language
- EN